AUS
NZ
UK
CA
USA
IND
Highlights
- Pre-Clinical Initiative: A pre-clinical study has been launched at the University Medical Centre of the Johannes Gutenberg University in Mainz to assess Gen2 real-time imaging technology on gastrointestinal (GI) tract tissue.
- Collaborative Research: The study, conducted under the leadership of Professor Ralph Kiesslich, forms a crucial step in advancing imaging technology for diagnosing and managing GI diseases.
- Pathway to Future Developments: Data collected from the trial is expected to support the design and development of a Gen3 flexible endomicroscope and facilitate AI algorithm advancements in collaboration with Monash University.
A new chapter in the development of advanced gastrointestinal imaging has begun with a pre-clinical trial initiated by Optiscan Imaging Ltd (ASX:OIL). The study, taking place at the esteemed University Medical Centre of the Johannes Gutenberg University in Mainz, Germany, aims to rigorously assess the Gen2 real-time imaging capability on GI tract tissues. The research site has successfully completed key preparatory activities, including the development and deployment of the first imaging prototype designed to capture detailed visuals of the gastrointestinal tract.
In a significant milestone for the project, the first prototype—integral to capturing high-quality images—has been installed and tested at the facility. This prototype is tailored specifically to address the complexities of the GI tract, a critical area in the diagnosis and management of a range of diseases, including cancer. The study is structured in a phased manner, beginning with pre-clinical data collection before moving to the clinical phase, which is scheduled for the forthcoming months.
The trial is being conducted under the expert supervision of world-renowned gastroenterologist Professor Ralph Kiesslich. His leadership, combined with the robust infrastructure at the University Medical Centre, ensures that the trial is being executed to the highest scientific and clinical standards. Detailed imaging data collected during the pre-clinical phase is anticipated to provide comprehensive insights into various GI disease processes. This information is crucial for refining the imaging technology and for paving the way towards more effective diagnostic and therapeutic procedures.
The study is also instrumental in laying the groundwork for future innovations. The insights gained from the Gen2 imaging assessments will contribute significantly to the engineering and development of the Gen3 flexible endomicroscope. This next-generation device is being designed to further enhance the visualization of internal tissue, potentially revolutionizing the approach to endoscopic examinations and interventions in GI diseases. The iterative process, moving from Gen2 to Gen3, reflects a methodical approach to technological advancement and clinical application.
In parallel with the imaging technology trials, data captured from the various disease processes within the GI tract is expected to initiate the development of advanced AI algorithms. These efforts are in collaboration with the CRC-P partner, Monash University, marking a critical intersection between medical imaging and artificial intelligence. The integration of AI aims to augment the precision and efficiency of image analysis, thereby enhancing the overall diagnostic capability of the system.
Dr Camile Farah, the CEO and managing director of Optiscan, has been actively involved in the groundwork of this study. A recent visit to Germany underscored the commitment to ensuring that the trial’s design and execution are aligned with the overarching goal of improving diagnostic accuracy and patient outcomes in the realm of gastrointestinal health. Preparations for the clinical phase were also solidified during this visit, marking a clear trajectory for the study as it moves into the next stages.
The strategic approach adopted in this trial underscores a commitment to addressing one of the most pressing global health challenges—GI diseases. Early detection remains paramount in managing these conditions effectively, and current diagnostic tools have often been limited in their capacity to provide rapid, accurate assessments. By leveraging cutting-edge imaging technology, the trial is expected to offer enhanced clarity in visualizing tissue abnormalities, thereby contributing to more informed and timely clinical decisions.
The collaboration between Optiscan Imaging Ltd and leading academic institutions not only exemplifies the potential of international scientific cooperation but also highlights a focused endeavor to translate pre-clinical findings into tangible clinical applications. The study’s results are anticipated to inform future research and development initiatives, ultimately contributing to improved diagnostic and therapeutic protocols in gastroenterology.
In summary, this pre-clinical trial represents a significant step in advancing GI imaging technology. By bridging state-of-the-art imaging techniques with future innovations in endomicroscopy and AI, the study aims to redefine the landscape of gastrointestinal diagnostics. The outcomes of this research are expected to provide critical data that will drive the next wave of technological advancements, ensuring that the evolution of GI imaging continues to meet the complex challenges of modern medicine.
